Dihydrotestosterone
Specifications
521-18-6CAS Number
208-307-3EC Number
(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-oneIUPAC Name
C19H30O2Chemical Formula
290.4 g/molMolecular Weight
STANOLONE; Androstanolone; dihydrotestosterone; 521-18-6; Anabolex; Andractim; Androlone; Neodrol; 4-Dihydrotestosterone; Anaboleen; Proteina; Stanaprol; Protona; 5alpha-Dihydrotestosterone; Cristerona MB; 17beta-Hydroxy-5alpha-androstan-3-one; Androstanolona; 5alpha-Androstan-17beta-ol-3-one; 5-alpha-Dihydrotestosterone; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; Androstanolonum; 5alpha-DHT; Androstalone; Dihydrotestosteron; 17beta-Hydroxy-3-androstanone; dihydrotestosterone (dht); Androstan-17beta-ol-3-one; 5alpha,17beta-Hydroxyandrostan-3-one; DTXSID9022364; NSC-10972; CHEBI:16330; 08J2K08A3Y; Androstan-3-one, 17-hydroxy-, (5alpha,17beta)-; 17beta-Hydroxy-5alpha-androstane-3-one; DTXCID202364; (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (5alpha,17beta)-17-hydroxyandrostan-3-one; NSC10972; (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta(a)phenanthren-3-one; 17 beta Hydroxy 5 beta Androstan 3 One; 5 alpha DHT; 5-alpha-DHT; RefChem:587772; 5 beta Dihydrotestosterone; 5 alpha Dihydrotestosterone; 5 alpha-Dihydrotestosterone; 5-alpha Dihydrotestosterone; Dihydrotestosterone, 5-alpha; THERAPEUTIC ANDROSTANOLONE; A14AA01; G03BB02; LG152; 17beta Hydroxy 5alpha Androstan 3 One; beta-Hydroxy-5 beta-Androstan-3-One, 17; (1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo(8.7.0.02,7.011,15)heptadecan-5-one; 208-307-3; DHT; Stanorone; NSC 10972; 5a-Dihydrotestosterone; Androstanolone [INN]; 17-beta-Hydroxy-5-alpha-androstan-3-one; 5alpha-dihydrotesosterone; 5alpha dihydrotestosterone; 5.alpha.-Dihydrotestosterone; 5alpha-Androstan-3-one, 17beta-hydroxy-; CHEMBL27769; 4,5.alpha.-Dihydrotestosterone; 17beta-Hydroxy-androstan-3-one; 5-alpha-Androstan-3-one, 17-beta-hydroxy-; 17.beta.-Hydroxy-3-androstanone; (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; Androstanolone (INN); 5.alpha.-Androstan-17.beta.-ol-3-one; NCGC00091013-01; Stanolon; 5.alpha.,17.beta.-Hydroxyandrostan-3-one; [3H]DHT; BDBM50366473; 5alpha-Dihydroxytestosterone; Androstanolone (1mg/ml in Acetonitrile); Androstanolonum [INN-Latin]; (1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-one; CAS-521-18-6; Androstanolona [INN-Spanish]; 4,5-alpha-Dihydrotestosterone; 5-.alpha.-Androstanolone; Androstanolone (1.0 mg/mL in Acetonitrile); 5.alpha.-Androstan-3-one, 17.beta.-hydroxy-; [3H]dihydrotestosterone; [3H]-dihydrotestosterone; EINECS 208-307-3; 5alpha,17eta-Hydroxyandrostan-3-one; Androstan-17.beta.-ol-3-one; 5-alpha-Androstan-17-beta-ol-3-one; 17-beta-hydroxyandrostan-3-one; Androstan-3-one, 17-hydroxy-, (5.alpha.,17.beta.)-; Andrin; UNII-08J2K08A3Y; (+)-Androstan-17.beta.-ol-3-one; 521-18-6 (free); 1kdk; 2ama; Androstan-3-one, 17-hydroxy-, (5a,17b)-; (5-alpha,17-beta)-17-Hydroxyandrostan-3-one; Andractim (TN); 5-a-Androstanolone; 5alpha-Androstanolone; Androstanolone (DHT); 17-.beta.-Hydroxy-5-.alpha.-androstan-3-one; 5-alpha-Androstanolone; 1d2s; 1t5z; 1t7r; STANOLONE [MI]; Stanolone; Androstanolone; (5.alpha.,17.beta.)-17-Hydroxy-androstan-3-one; 4,5a-Dihydrotestosterone; Androstan-17b-ol-3-one; Epitope ID:135868; 17-Hydroxyandrostan-3-one, (5.alpha.,17.beta.)- #; EC 208-307-3; 17b-Hydroxy-3-androstanone; BIDD:PXR0075; SCHEMBL15163; 17-Hydroxy-androstan-3-one; MLS001304063; 5a-Androstan-17b-ol-3-one; BIDD:ER0136; 5.alpha.-Dihydroxytestosterone; 5A-Androstan-3-on-17B-ol; 5B-Androstan-3-on-17B-ol; ANDROSTANOLONE [MART.]; GTPL2856; GTPL3455; orb2647466; ANDROSTANOLONE [WHO-DD]; BDBM18161; 1t63; (+)-Androstan-17beta-ol-3-one; HMS2272H05; 5alpha-Dihydrotestosterone degrees; HY-A0120; Tox21_111056; Tox21_200987; Tox21_303655; LMST02020042; MSK8502-100A; s4757; AKOS015894892; CCG-267385; CS-5096; DB02901; FA17912; GS-6587; (5a,17b)-17-Hydroxyandrostan-3-one; NCGC00091013-02; NCGC00091013-03; NCGC00257456-01; NCGC00258540-01; (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one; 17beta-hydroxy-3-oxo-5alpha-androstanone; AC-16144; AC-33095; BP-45795; SMR000058342; NS00005234; TESTOSTERONE IMPURITY F [EP IMPURITY]; 5alpha-Androstan-17beta-ol-3-one, >=97.5%; C03917; D07456; Dihydrotestosterone; Testosterone EP Impurity F; 5Alpha-Dihydrotestosterone, 1mg/ml in Acetonitrile; Q411054; 17.BETA.-HYDROXY-5.ALPHA.-ANDROSTAN-3-ONE; 17.BETA.-HYDROXY-5.ALPHA.-ANDROSTANE-3-ONE; Androstanolone (5alpha-Dihydrotestosterone, Stanolone); BRD-K22525962-001-05-0; Dihydrotestosterone Solution in Acetonitrile, 100ug/mL; 5alpha-Androstan-17beta-ol-3-one, purum, >=99.0% (TLC); 5alpha-Androstan-17beta-ol-3-one, VETRANAL(TM), analytical standard; Androstanolone (5alpha-Dihydrotestosterone, Stanolone) 1.0 mg/ml in Acetonitrile; (5S,8R,10S,13S,17S)-17-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one; 17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,10,11,12,13,14,15,16, 17-hexadecahydrocyclopenta[a]phenanthren-3-oneSynonyms
